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Alzheimer’s disease (AD) is the most common form of dementia and it is characterized to be an age-related and progressive neurodegenerative disorder which main consequences are cognitive impairment and memory loss. The AD brain histological hallmarks are the 
formation of senile plaques , composed of Aβ peptides, and neurofibrillary tangles (NFTs), formed by hyperphosphorilated tau (pTau) protein.  
The origin of the disease still remains unclear but some hypothesis have been proposed. The first were the amyloid cascade and the tau protein hypothesis. Recent evidence suggest a hypothesis that consist of a metabolic disorder, which consider insulin resistance as a 
pathological key that leads to the other features of AD. Because of the role that insulin plays in T2DM, it set up a link between AD and T2DM suggesting that studying both disease in parallel  would  bring some new clues to discover the “lasts pieces of the puzzle”.  
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CONCLUSIONS 
AD is a multifactorial disease and that is why finding an efficient therapeutic treatment is so challenging. Apparently, the mechanism of the different pathological features are 
interconnected, and global vision it has been provided by the hypothesis of metabolic disorder. 
Taking all those mechanism in account, it seems that brain insulin resistance is the common feature between them. It could confirm that there is a link between AD and T2DM and it 
has been thought that it would uncover the way to understand the pathogenic mechanism of AD and put together “the pieces of the puzzle”. Hence, there is confidence in the fact that 
many therapy strategies based on insulin as a therapeutic target may yield promising results. 
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Figure 3. Possible AβO and tau interaction [1]  
Figure 2. Insulin signal pathway [2] 
Figure 3. Possible mechanism through insulin mediates other AD pathologies [3]  
THE AMYLOID CASCADE 
HYPOTHESIS 
• Deposition of Aβ peptides in early-
onset AD due to mutations in APP, 
PSEN1 and PSEN2. In late-onset AD 
are associated with ApoE4. 
• Amyloid plaques  neurotoxicity 
(ROS) and dysregulation of 
intracellular Ca2+. 
• Recent studies: AβOs  are the 
neurotoxic agents rather than 
plaques. 
THE TAU PROTEIN 
HYPOTHESIS 
• Tau is a MAP protein, regulates MT 
and axonal transport of organelles 
 critical for neurotransmission. 
• pTau  self-assembles into NTF 
which alter MT function, ↓ axonal 
trafficking  synapsis loss  cell 
death.  
BRAIN INSULIN EFFECT 
o Brain insulin is derived from peripheral insulin and transferred 
across the BBB but there is also data of local insulin synthesis in 
the brain.  
 
 
METABOLIC DISORDER HYPOTHESIS 
It defends that a metabolic disorder  precedes cognitive dysfunction and 
pathological alterations of AD. 
  Metabolic abnormalities includes disrupted glucose uptake and 
impaired energy metabolism. It is associated with brain insulin 
deficiency and dysregulated signal transduction. 
  Those features resembles T2DM and carry some researchers to 
that question: 
 
 
 
 IS AD A BRAIN-SPECIFIC FORM OF DIABETES? 
 
 
 
 
 
 
 
 
 
  
GLUCOSE METABOLISM 
It is suggested that insulin modulates CMRglu and glucose uptake within the hippocampus and 
cortex. Several hypotheses of the mechanism have been reported: 
 
 Decrease of GLUTs could be due to insulin/IGF-1 signalling defects due to PI3K/Akt 
pathway. 
 Insulin might influence CMRglu through GLUT4 (an insulin-sensitive GLUT) 
 GLUT1 and GLUT3 may result from down-regulation of HIF-1 (possibly decreased in AD due 
to increased oxidative stress. 
APP AMYLOIDOGENESIS 
It has been proposed that insulin promotes Aβ formation and secretion into extracellular 
space in a PI3K-dependent manner. 
 
 Disrupted insulin signalling could induce APP amyloidogenesi via PI3K/Akt/GSK-3α. 
 Disrupted insulin seems to accelerate APP/Aβ trafficking to extracellular space via MAPK.  
 Aβ peptides might reduce the affinity of the binding between insulin and IR. 
 In hyperinsulinemia situation there is ↓ IDE activity  ↑Aβ deposition 
 Aβ peptides may induce the removal of IR from the membrane  
HYPERPHOSPHRYLATION OF TAU 
It has been reported that insulin and glucose metabolism regulate phosphorylation of tau. 
 
 MAPK, CdK5 and GSK-3β are the major tau kinases 
 Insulin, via GSK-3β, could ↓ PP2A  ↑pTau 
 A decrease of GLUTs may involve a ↓HBP flux  ↓ of O-GlcNAcylation ↑pTau 
NEUROINFLAMMATION 
It has been suggest that impaired insulin signalling could be due to pro-inflammatory 
signalling. 
 
 Peripheral inflammatory factors, trauma, infection of abnormal protein aggregates activate 
MG  ↑TNF-α, IL-6 and IL-1β. 
 TNF-α binds to TNF-αR and through stress-sensitive kinases (JNK, IKK and PKR) inhibits IRS 
function  ↑GSK-3α  ↑ APP amyloidogenesi  
 ↑ APP amyloidogenesi, via Aβ aggregation, induces reactive MG. 
BRAIN INSULIN AS A THERAPEUTIC TARGET OF AD 
